Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

Shimei WANG; Liping WU; Ling HU

doi:10.3969/j.issn.1001-5256.2023.01.031

Volume 39 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(1): 199-203

PDF( 1745 KB)

Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

DOI: 10.3969/j.issn.1001-5256.2023.01.031

Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, China

Research funding:

Science and Technology Project of Chengdu (2021-YF05-00585-SN);

Seientific Research Project of Chengdu's Municipal Health Commission (2022484)

More Information

Corresponding author: WANG Shimei, wangshimei712@163.com (ORCID: 0000-0002-1222-7259)
Received Date: 2022-05-07
Accepted Date: 2022-06-30
Published Date: 2023-01-20

Abstract

Abstract

Portal vein thrombosis is one of the common complications of liver cirrhosis, and anticoagulation is currently the main treatment method for this disease. Since low-molecular-weight heparin must be injected and vitamin K antagonists require regular monitoring of international normalized ratio (INR), direct oral anticoagulants have become a research hotspot in replacement therapy with the advantages of convenient oral administration, no need for INR monitoring, and high recanalization rate. This article summarizes the advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis, in order to lay a foundation for further clinical studies.
- Liver Cirrhosis,
- Anticoagulants,
- Rivaroxaban

FullText(HTML)

References(32)

References

[1]	KOH JH, LIEW ZH, NG GK, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(1): 56-62. DOI: 10.1016/j.dld.2021.07.039.
[2]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Dig Dis, 2021, 22(4): 176-186. DOI: 10.1111/1751-2980.12970.
[3]	PRIYANKA P, KUPEC JT, KRAFFT M, et al. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis[J]. Int J Hepatol, 2018, 2018: 8432781. DOI: 10.1155/2018/8432781.
[4]	NORONHA FERREIRA C, REIS D, CORTEZ-PINTO H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J]. Dig Dis Sci, 2019, 64(9): 2671-2683. DOI: 10.1007/s10620-019-05572-z.
[5]	NAYMAGON L, TREMBLAY D, ZUBIZARRETA N, et al. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis[J]. Dig Dis Sci, 2021, 66(10): 3619-3629. DOI: 10.1007/s10620-020-06695-4.
[6]	WANG L, GUO X, XU X, et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: Results of a meta-analysis[J]. Adv Ther, 2021, 38(1): 495-520. DOI: 10.1007/s12325-020-01550-4.
[7]	DONG S, QI H, LI Y, et al. A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?[J]. Hepatol Int, 2021, 15(6): 1356-1375. DOI: 10.1007/s12072-021-10233-3.
[8]	PETTINARI I, VUKOTIC R, STEFANESCU H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J]. Am J Gastroenterol, 2019, 114(2): 258-266. DOI: 10.1038/s41395-018-0421-0.
[9]	GHAZALEH S, BERAN A, ABURAYYAN K, et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Ann Gastroenterol, 2021, 34(1): 104-110. DOI: 10.20524/aog.2020.0544.
[10]	GAO Y, LIU H, TANG F, et al. Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101649. DOI: 10.1016/j.clinre.2021.101649.
[11]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76(5): 1151-1184. DOI: 10.1016/j.jhep.2021.09.003.
[12]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[13]	O'LEARY JG, GREENBERG CS, PATTON HM, et al. AGA Clinical Practice Update: coagulation in cirrhosis[J]. Gastroenterology, 2019, 157(1): 34-43. e1. DOI: 10.1053/j.gastro.2019.03.070.
[14]	NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 73(1): 366-413. DOI: 10.1002/hep.31646.
[15]	ELHOSSEINY S, AL MOUSSAWI H, CHALHOUB JM, et al. Direct oral anticoagulants in cirrhotic patients: Current evidence and clinical observations[J]. Can J Gastroenterol Hepatol, 2019, 2019: 4383269. DOI: 10.1155/2019/4383269.
[16]	DOUROS A, AZOULAY L, YIN H, et al. Non-Vitamin K antagonist oral anticoagulants and risk of serious liver injury[J]. J Am Coll Cardiol, 2018, 71(10): 1105-1113. DOI: 10.1016/j.jacc.2018.01.009.
[17]	LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.
[18]	YAO W, FENG Y, LIU T, et al. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial[J]. EXCLI J, 2021, 20: 537-549. DOI: 10.17179/excli2020-3120.
[19]	NAGAOKI Y, AIKATA H, DAIJYO K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis[J]. Hepatol Res, 2018, 48(1): 51-58. DOI: 10.1111/hepr.12895.
[20]	MORT JF, DAVIS J, MAHORO G, et al. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2021, 19(7): 1436-1442. DOI: 10.1016/j.cgh.2020.08.007.
[21]	SEMMLER G, POMEJ K, BAUER D, et al. Safety of direct oral anticoagulants in patients with advanced liver disease[J]. Liver Int, 2021, 41(9): 2159-2170. DOI: 10.1111/liv.14992.
[22]	AI MH, DONG WG, TAN XP, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2020, 32(10): 1395-1400. DOI: 10.1097/MEG.0000000000001846.
[23]	COSTACHE RS, DRAGOMIRICǍ AS, DUMITRAŞ EA, et al. Portal vein thrombosis: A concise review (Review)[J]. Exp Ther Med, 2021, 22(1): 759. DOI: 10.3892/etm.2021.10191.
[24]	CHUN HS, CHOE AR, LEE M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis[J]. Clin Mol Hepatol, 2021, 27(4): 535-552. DOI: 10.3350/cmh.2021.0109.
[25]	NG CH, TAN D, NISTALA K, et al. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis[J]. Hepatol Int, 2021, 15(5): 1196-1206. DOI: 10.1007/s12072-021-10247-x.
[26]	MOHAN BP, ARAVAMUDAN VM, KHAN SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis[J]. Ann Gastroenterol, 2020, 33(5): 521-527. DOI: 10.20524/aog.2020.0503.
[27]	DAVIS KA, JOSEPH J, NISLY SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes[J]. J Thromb Thrombolysis, 2020, 50(2): 457-461. DOI: 10.1007/s11239-019-02035-0.
[28]	CHEN H, LEI J, LIANG S, et al. Safety and efficacy of anticoagulation in patients with cirrhosis: A Meta-Analysis[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8859602. DOI: 10.1155/2021/8859602.
[29]	HANAFY AS, ABD-ELSALAM S, DAWOUD MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J]. Vascul Pharmacol, 2019, 113: 86-91. DOI: 10.1016/j.vph.2018.05.002.
[30]	WILLIAMS C, STEWART E, CONZEN KD, et al. Dabigatran reversal with idarucizumab in 2 patients with portal vein thrombosis undergoing orthotopic liver transplantation[J]. Semin Cardiothorac Vasc Anesth, 2021, 25(3): 200-207. DOI: 10.1177/1089253220982183.
[31]	DIBIASI C, WIEGELE M, GRATZ J. Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis[J]. J Clin Anesth, 2019, 56: 41-42. DOI: 10.1016/j.jclinane.2019.01.020.
[32]	HUANG ZC, LI CQ, LIU XY, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review[J]. Cardiovasc Drugs Ther, 2021, 35(6): 1205-1215. DOI: 10.1007/s10557-020-07065-y.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1821) PDF downloads(146)

Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

DOI: 10.3969/j.issn.1001-5256.2023.01.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

DOI: 10.3969/j.issn.1001-5256.2023.01.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content